Loading
Endometrial and Cervical Cancer Treatments · Journal article
Medicina · August 17, 2026
Raises a question worth testing. It does not answer one.
This narrative review examines whether dysregulation of gut and reproductive tract microbiota in endometriosis may act as a biological modulator contributing to endometrial carcinogenesis through intersecting endocrine, inflammatory, metabolic, immune, oxidative, and barrier-related pathways. The authors conclude that microbiome dysbiosis should be regarded as a hypothetical contributory factor rather than an established causal driver, and that current evidence is limited by methodological constraints, with near-term translational potential primarily in biomarker development and risk stratification rather than immediate therapeutic intervention.
Narrative review. Individuals with endometriosis and endometrial carcinogenesis; review integrates evidence on gut and reproductive tract microbiota alterations relevant to endometrial homeostasis.
Loss of Lactobacillus dominance and enrichment of anaerobic pro-inflammatory taxa proposed as contributing to dysbiosis-related carcinogenesis risk Dysbiosis may influence endometrial carcinogenesis through altered estrogen recirculation, progesterone resistance, Toll-like receptor activation, NF-κB/STAT3 signaling, COX-2/PGE2 activity, and PI3K/AKT/mTOR pathway activation Current literature limited by small and heterogeneous cohorts, predominantly cross-sectional designs, contamination risk, and marked methodological variability in low-biomass uterine samples
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should view dysbiosis-associated endometrial carcinogenesis risk as mechanistically plausible but not yet causally established. Current evidence supports investigation of microbiome signatures for risk biomarkers and stratification rather than routine microbiome-directed preventive or therapeutic strategies in endometrial cancer management.
This narrative review proposes a mechanistic hypothesis linking endometriosis-associated dysbiosis to endometrial carcinogenesis through multiple interconnected pathways, but acknowledges that current evidence remains limited by small heterogeneous cohorts, cross-sectional designs, and methodological variability, with dysbiosis characterized as a hypothetical rather than established causal driver.
As stated by the source record.
Clinicians should view dysbiosis-associated endometrial carcinogenesis risk as mechanistically plausible but not yet causally established. Current evidence supports investigation of microbiome signatures for risk biomarkers and stratification rather than routine microbiome-directed preventive or therapeutic strategies in endometrial cancer management.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Background and Objectives: Endometriosis is associated with chronic inflammation, immune dysregulation, oestrogen-dependent growth, oxidative stress, altered steroid hormone metabolism, compromised epithelial barrier integrity, and the production of bioactive microbial metabolites. These interconnected alterations have been proposed to create, in principle, a permissive local microenvironment for malignant transformation. This narrative review examines whether endometriosis-associated dysregulation of the gut and reproductive tract microbiota may act as a hypothetical biological modulator linking these multi-axis changes to endometrial carcinogenesis, with attention to immunological, endocrine, metabolic, microbial–metabolite, oxidative, and barrier-related pathways. Material and Methods: We narratively integrated current evidence on gut and reproductive tract microbiota alterations relevant to endometrial homeostasis, with emphasis on the estrobolome, low-biomass uterine microbial communities, inflammatory and immune signaling, microbial metabolites, and pathways implicated in carcinogenesis. Results: Available data suggest that dysbiosis may influence endometrial carcinogenesis through interconnected endocrine, inflammatory, metabolic, and immune mechanisms. Attention has been given to loss of Lactobacillus dominance, enrichment of anaerobic and pro-inflammatory taxa, altered estrogen recirculation, progesterone resistance, Toll-like receptor activation, NF-κB/STAT3 signaling, COX-2/PGE2 activity, PI3K/AKT/mTOR pathway activation, oxidative stress, macrophage polarization, and impaired natural killer cell surveillance. These alterations may contribute to a permissive microenvironment characterized by persistent inflammation, defective immune control, and disrupted endometrial homeostasis. However, the current literature remains limited by small and heterogeneous cohorts, predominantly cross-sectional designs, contamination risk, and marked methodological variability, particularly in low-biomass uterine samples. Conclusions: Current evidence supports the view that microbiome dysregulation is a context-dependent biological modulator that intersects with endocrine, inflammatory, metabolic, immune, oxidative, and barrier-related pathways relevant to endometrial carcinogenesis. Microbiome dysbiosis should be regarded as a hypothetical contributory factor rather than as an established causal driver. Its near-term translational relevance appears greater for biomarker development and risk stratification than for immediate microbiome-directed therapy. Longitudinal, standardized, and functionally integrated studies are needed to clarify whether microbiome-associated signatures can be translated into clinically meaningful prevention and management strategies in endometrial cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.